Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RGNX
REGENXBIO INC.
NASDAQ
$9.66
▲ UP 3.09% (0.29)

KEY STATISTICS

Market Cap$499.40 M
52w High$16.19
52w Low$5.46
Dividend Yield—
Frequency—
P/E-2.55
Volume1.75M
Shares Out.51.70M

COMPANY

LEADERSHIP

Curran Simpson
CHIEF EXECUTIVE
Curran Simpson

COMPENSATION 2026

Salary$665,510
Stock Awards$777,448
Incentive Plan Pay$387,327
All Other Comp.$20,125
Total$4,200,712

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 17, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
371

PRICE TARGET

Target High$29.00
Target Low$12.00
Target Median$18.00
Target Consensus$19.60

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$15.86M
NOV
5
THU

PRICE

$9.66 ▲ UP 3.09% (+$0.29)
$9.25$9.50$9.75$10.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM9.66

About REGENXBIO Inc.

https://www.regenxbio.com ↗

REGENXBIO Inc. is a biotech company developing gene therapies using its NAV AAV platform, with lead candidates in clinical trials for eye, neurological, and muscular diseases, and licensing its technology to other firms.

INDUSTRY

Biotechnology

A PRODUCT REGENXBIO INC. IS KNOWN FOR

RGX-202
RGX-202

An investigational one-time gene therapy delivering a microdystrophin transgene for Duchenne muscular dystrophy, showing promising clinical data and planned BLA submission.

COMPETITORS

COMPETITOR
EWTX COMPARE
PFE COMPARE
PTCT COMPARE
SLDB COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License and Service$23.61M $27.15M ▲$5.09M ▼$103.84M ▲
Service$6.13M $3.19M ▼$1.3M ▼$4.18M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
112
LISTED HERE
24
RANKED BY POSITION SIZE
XBI
0.16% · 2.1M
VTS.AX
0.00% · 1.8M
IWM
0.01% · 1.3M
FESM
0.05% · 370.0K
SCHA
0.01% · 234.4K
DFAC
0.00% · 145.4K
PRFZ
0.04% · 105.5K
LABU
0.11% · 75.9K
BBC
0.84% · 47.1K
XRSU.L
0.01% · 42.8K
HAPS
0.21% · 40.0K
GNOM
0.35% · 33.0K
WDNA.L
0.63% · 22.8K
FSML
0.11% · 18.2K
GINN
0.06% · 11.8K
SCDS
0.25% · 2.5K
URTY
0.01% · 2.0K
TNXT
0.07% · 1.3K
VETS
0.03% · 1.1K
DM
DMRS
0.09% · 1.0K
KBFR
0.06% · 701
SYZ
0.00% · 270
AVSU
0.00% · 166
RESM
0.01% · 91

INSTITUTIONAL OWNERSHIP

SHARES OWNED
76.36%
HOLDERS
285
TOP 12 OF 285 · RANKED BY POSITION SIZE
Blackrock Inc.
8.6M sh · $100.73M
Blackrock, Inc.
6.4M sh · $76.64M
Redmile Group, LLC
4.7M sh · $45.29M
Jpmorgan Chase & Co
4.0M sh · $38.96M
Vanguard Group Inc
3.4M sh · $48.59M
State Street Corp
3.0M sh · $35.59M
Morgan Stanley
2.1M sh · $17.31M
Goldman Sachs Group Inc
1.9M sh · $17.87M
Integral Health Asset Management, LLC
1.5M sh · $12.57M
Aqr Capital Management LLC
1.4M sh · $16.51M
Qube Research & Technologies Ltd
1.3M sh · $10.98M
Marshall Wace, Llp
1.3M sh · $15.39M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

TRADES BY CONGRESS

HOUSE TRADES
Peter Welch
Peter Welch
Sale (Full)
2019-11-08

INSIDER TRADES

★
DIRECTOR
Ciongoli Gregory Austin
Purchase · 53.4K shares
2026-08-27
★
DIRECTOR
Ciongoli Gregory Austin
Purchase · 69.6K shares
2026-08-25
★
DIRECTOR
Ciongoli Gregory Austin
Purchase · 49.2K shares
2026-08-26
★
DIRECTOR
Ciongoli Gregory Austin
Purchase · 15.4K shares
2026-08-25

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OUTPERFORM 3
EQUAL WEIGHT 1
OVERWEIGHT 1
NEUTRAL 1
10 GRADES IN THE LAST 12 MONTHS
Baird OUTPERFORM HC Wainwright & Co. BUY Barclays EQUAL WEIGHT Leerink Partners OUTPERFORM B of A Securities BUY Morgan Stanley OVERWEIGHT Goldman Sachs NEUTRAL Chardan Capital BUY

SECTORS PEERS

PEERPRICE
ABSI$8.71COMPARE
MLTX$14.99COMPARE
CRVS$14.16COMPARE
OLMA$10.27COMPARE
FDMT$14.67COMPARE
VSTM$7.22COMPARE
PRTA$9.33COMPARE
GOSS$0.17COMPARE